. 2024 Feb 18;16(4):828. doi: 10.3390/cancers16040828

Table 3.

Influence of selected demographic and clinical variables on overall survival.

Variable	mOS (Months)	Univariable		Multivariable
Variable	mOS (Months)	HR [95% CI]	p	HR [95% CI]	p
Sex
Women	49	0.90 [0.48–1.68]	0.7288	0.69 [0.33–1.44]	0.3292
Men	NR	0.90 [0.48–1.68]	0.7288	0.69 [0.33–1.44]	0.3292
Age
<75 years	43	0.70 [0.29–1.73]	0.4946	0.69 [0.25–1.94]	0.4853
≥75 years	NR	0.70 [0.29–1.73]	0.4946	0.69 [0.25–1.94]	0.4853
Tumor localization
U, M	33	0.42 [0.22–0.78]	0.0189 *	0.65 [0.27–1.54]	0.3274
L	NR	0.42 [0.22–0.78]	0.0189 *	0.65 [0.27–1.54]	0.3274
Lauren histological type
Intestinal	NR	0.43 [0.23–0.79]	0.0057 *	0.63 [0.32–1.24]	0.1848
Diffuse/Mixed	25	0.43 [0.23–0.79]	0.0057 *	0.63 [0.32–1.24]	0.1848
(y)pT
0–3	54	1.98 [0.82–4.77]	0.0502 *	1.37 [0.65–2.90]	0.4098
4	17	1.98 [0.82–4.77]	0.0502 *	1.37 [0.65–2.90]	0.4098
(y)pN
N0	NR	3.54 [1.93–6.49]	0.0001 *	3.41 [1.64–7.12]	0.0011 *
N+	18	3.54 [1.93–6.49]	0.0001 *	3.41 [1.64–7.12]	0.0011 *
Histopathological grading
G3	NR	2.03 [1.12–3.71]	0.0193 *	0.56 [0.29–1.08]	0.0844
G1, G2	26	2.03 [1.12–3.71]	0.0193 *	0.56 [0.29–1.08]	0.0844
Neoadjuvant chemotherapy
Yes	54	0.45 [0.17–1.19]	0.0593 *	0.40 [0.18–0.90]	0.0278 *
No	8	0.45 [0.17–1.19]	0.0593 *	0.40 [0.18–0.90]	0.0278 *
Tumor regression grade
3, 4	NR	0.24 [0.10–0.55]	0.0304 *	0.33 [0.07–1.45]	0.1441
1, 2	43	0.24 [0.10–0.55]	0.0304 *	0.33 [0.07–1.45]	0.1441
Type of gastrectomy
Proximal, Distal	NR	2.32 [1.24–4.33]	0.0041 *	2.77 [1.45–5.31]	0.0022 *
Total	16	2.32 [1.24–4.33]	0.0041 *	2.77 [1.45–5.31]	0.0022 *
TO
No	31	0.51 [0.28–0.93]	0.0269 *	0.42 [0.22–0.81]	0.0094 *
Yes	NR	0.51 [0.28–0.93]	0.0269 *	0.42 [0.22–0.81]	0.0094 *
Adjuvant chemotherapy
No	49	0.64 [0.31–1.31]	0.1877	0.54 [0.25–1.18]	0.1246
Yes	NR	0.64 [0.31–1.31]	0.1877	0.54 [0.25–1.18]	0.1246
LMR
Low	NR	0.86 [0.47–2.57]	0.6157	0.82 [0.44–1.54]	0.5438
High	54	0.86 [0.47–2.57]	0.6157	0.82 [0.44–1.54]	0.5438
PLR
Low	62	1.46 [0.80–2.67]	0.1975	1.07 [0.55–2.06]	0.8436
High	25	1.46 [0.80–2.67]	0.1975	1.07 [0.55–2.06]	0.8436
NLR
Low	NR	2.58 [1.41–4.73]	0.0017 *	2.55 [1.32–4.94]	0.0056 *
High	18	2.58 [1.41–4.73]	0.0017 *	2.55 [1.32–4.94]	0.0056 *
IBI
Low	NR	1.91 [1.05–3.48]	0.0337 *	2.56 [1.28–5.13]	0.0083 *
High	27	1.91 [1.05–3.48]	0.0337 *	2.56 [1.28–5.13]	0.0083 *

mOS—median overall survival, HR—hazard ratio, CI—confidence interval, U—upper, M—median, L—lower, ypT—post-neoadjuvant pathological tumor stage, ypN—post-neoadjuvant pathological nodal stage, TO—textbook outcome, LMR—lymphocyte/monocyte ratio, PLR—platelet/lymphocyte ratio, NLR—neutrophil/lymphocyte ratio, IBI—inflammatory burden index, *—statistical significance.